- Featured Product
- KD/KO Validated
B4GALT7 Polyclonal antibody
B4GALT7 Polyclonal Antibody for ELISA
验证数据展示
发表文章中的应用
| KD/KO | See 1 publications below |
| WB | See 1 publications below |
产品信息
10535-1-AP targets B4GALT7 in WB, ELISA applications and shows reactivity with human samples.
| Tested Applications | ELISA |
| Cited Applications | WB |
| Tested Reactivity | human |
| Cited Reactivity | human |
| Immunogen | B4GALT7 fusion protein Ag0793 种属同源性预测 |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Full Name | xylosylprotein beta 1,4-galactosyltransferase, polypeptide 7 (galactosyltransferase I) |
| Synonyms | B4GAL T7, B4GALT7, Beta 1,4 GalTase 7, beta4Gal T7, XGALT 1, XGALT1, XGPT, XGPT1 |
| Calculated Molecular Weight | 37 kDa |
| Observed Molecular Weight | 37 kDa |
| GenBank Accession Number | BC007317 |
| Gene Symbol | B4GALT7 |
| Gene ID (NCBI) | 11285 |
| RRID | AB_2274457 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | Q9UBV7 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
背景介绍
B4GALT7 (Beta-1,4-galactosyltransferase 7), also known as galactosyltransferase I, is involved in the formation of proteoglycans which are components of the extracellular matrix in connective tissues (PubMed: 10438455). The reduced activity of B4GALT7 results in delayed wound repair, altered migration, adhesion and contractility of patient fibroblasts (PMID: 16583246, PMID: 18158310). Mutations in B4GALT7 that also result in Spondylodysplastic (PMID: 24755949, PMID: 12417421).
实验方案
| Product Specific Protocols | |
|---|---|
| WB protocol for B4GALT7 antibody 10535-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
发表文章
| Species | Application | Title |
|---|---|---|
Eur J Hum Genet Impairment of glycosaminoglycan synthesis in mucopolysaccharidosis type IIIA cells by using siRNA: a potential therapeutic approach for Sanfilippo disease.
|